BRIEF-Gilead Sciences lists EPCLUSA on public drug plan to treat chronic hepatitis C infection
March 21 Gilead Sciences Inc -
* British Columbia lists EPCLUSA on public drug plan to treat all six genotypes of chronic hepatitis C infection Source text for Eikon: Further company coverage:
REFILE-India's Infosys says reassessing long-term goals due to tougher market
Bengaluru, June 24 Infosys Ltd, India's second-biggest software services exporter, is re-evaluating its long-term targets because tougher market conditions have made them appear "daunting", the company's chairman said on Saturday.